- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05344209
Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer (LUNGVAC)
A Randomized Phase II, Open-label, Multicenter Study Investigating Efficacy and Safety of Pembrolizumab +/- UV1 Vaccination as First Line Treatment in Patients With Inoperable Advanced or Metastatic Non-small Cell Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The objective of the phase 2 study is to induce a meaningful Progression-Free Survival (PFS) benefit in patients with stage IIIB/IIIC or stage IV NSCLC by treating with anti-PD-1/PD-L1 treatment and UV1 vaccination versus anti-PD-1/PD-L1 treatment alone.
Patients are randomized to receive anti-PD-1/PD-L1 treatment until progression or unacceptable toxicity, for a maximum of 2 years, with or without 8 injections of 300 μg UV1 and 75 μg GM-CSF (UV1 vaccination). Patients randomized to UV1 vaccination, will start UV1 vaccination the same day as anti-PD-1/PD-L1 treatment is initiated, followed by three vaccinations over the next ten days. Thereafter, one vaccination per anti-PD-1/PD-L1 treatment cycle (c2-5), totaling to 8 UV1 vaccinations
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Odd Terje Brustugun, Md, PhD
- Phone Number: 0047 32804029
- Email: otr@vestreviken.no
Study Contact Backup
- Name: Inger Johanne Zwicky Eide, MD
- Phone Number: 0047 32802991
- Email: ingei@vestreviken.no
Study Locations
-
-
Viken
-
Drammen, Viken, Norway, 3004
- Recruiting
- Vestre Viken Health Trust
-
Contact:
- Odd Terje Brustugun, MD,pHd
- Phone Number: +4732862464
- Email: otr@vestreviken.no
-
Contact:
- Inger-Johanne Eide, MD
- Phone Number: +4732862464
- Email: ingei@vestreviken.no
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed NSCLC stage IIIB/IIIC or IV not amenable for curative treatment, with PD-L1 ≥ 50% measured by a validated method, and eligible for pembrolizumab monotherapy in the first-line setting
- At least one lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline according to RECIST 1.1
- Subjects who received previous neo-adjuvant or adjuvant systemic therapy (other than immunotherapies) will be eligible if neo-adjuvant or adjuvant therapy was completed at least 12 months prior to the development of metastatic disease. Last dose of neoadjuvant or adjuvant therapy must be more than 12 months prior to enrollment/randomization
- Available unstained archived tumour tissue sample in sufficient quantity to allow for analyses. At least fifteen unstained slides or a tumour block (preferred)
- Male and female age ≥ 18 years at time of signing the ICF
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Adequate organ function as defined below
- Haemoglobin ≥9.0 g/dL
- Absolute neutrophil count (ANC) 1.5 x (> 1500 per mm3)
- Platelet count ≥100 x 109/L (>75,000 per mm3)
- Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN).
- AST (SGOT)/ALT (SGPT) ≤2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be ≤5x ULN
- Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine CL >40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:
Males:
Creatinine CL (mL/min) = Weight (kg) x (140 - Age) 72 x serum creatinine (mg/dL)
Females:
Creatinine CL (mL/min)
= Weight (kg) x (140 - Age) x 0.85 72 x serum creatinine (mg/dL)
- Written informed consent obtained prior to any study specific procedure
Exclusion Criteria:
- Previous treatment with a PD-1 or PD-L1 inhibitor, including pembrolizumab or any other agent targeting immune checkpoints
- Previous malignancy (except non-melanoma skin cancer and the following in situ cancers: bladder, gastric, esophageal, colon, endometrial, cervical, melanoma or breast) unless a complete remission was achieved at least 2 years prior to study entry
- Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids (prednisone >10 mg or equivalent). Surgery, radiation and/or corticosteroids (any dose >10 mg prednisone equivalent) must have been completed ≥ 2 weeks prior to registration
- Known history of leptomeningeal carcinomatosis
- Uncontrolled seizures.
- Current or prior use of immunosuppressive medication within 28 days before the first dose of pembrolizumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. Steroid premedication given as prophylaxis for imaging contrast allergy should not be counted for this criterion
- Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease, diverticulitis with the exception of diverticulosis, celiac disease, irritable bowel disease; Wegner syndrome) within the past 2 years. Subjects with vitiligo, alopecia, Grave's disease, or psoriasis not requiring systemic treatment (within the past 3 years) are not excluded
- History of primary immunodeficiency
- History of allogeneic organ transplant
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent
- Active infection including tuberculosis (clinical evaluation including: physical examination findings, radiographic findings, positive PPD test, etc.), hepatitis B (known positive HBV surface antigen [HBsAg] result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies as defined by a positive ELISA test). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. HIV testing is not required in the absence of clinical suspicion
- Pregnant or lactating women
- Live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving pembrolizumab
- Any condition that, in the opinion of the investigator, would interfere with the evaluation of study treatment or interpretation of patient safety or study results
- History of allergy or hypersensitivity to any of the active substances or excipients in the study drug
- Involvement in the planning and/or conduct of the study (investigator staff and/or staff at the study site)
- Judgment by the investigator that the subject should not participate in the study if the subject is unlikely to comply with study procedures, restrictions and requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: anti-PD-1/PD-L1 treatment + UV1 vaccination
anti-PD-1/PD-L1 treatment + UV1 vaccination (and sagramostim)
|
UV1 vaccine
for stimulation of local dendritic cell population to take up the vaccine and to mature into professional APCs
Other Names:
either pembrolizumab, atezolizumab or cemiplimab
|
Other: anti-PD-1/PD-L1 treatment
|
either pembrolizumab, atezolizumab or cemiplimab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST 1.1) as determined by Blinded Independent Central Review (BICR)
Time Frame: Up to 2 years
|
Evaluate and compare the efficacy of anti-PD-1/PD-L1-treatment with or without UV1 vaccination in patients with stage IIIB/IIIC or stage IV NSCLC.
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response evaluation
Time Frame: Throughout trial (up to 2 years)
|
Comparison of response rate according to RECIST v1.1 in patients who receive anti-PD-1/PD-L1 treatment and patients who receive anti-PD-1/PD-L1 treatment in combination with UV1.
|
Throughout trial (up to 2 years)
|
monitoring AE
Time Frame: continously and until 4 months after discontinuation of study treatment
|
evaluate safety and tolerability in patients who receive anti-PD-1/PD-L1 treatment and patients who receive anti-PD-1/PD-L1 treatment in combination with UV1.
|
continously and until 4 months after discontinuation of study treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
molecular characterization and analyses
Time Frame: up to 2 years
|
investigate for possible biological markers for response, resistance and toxicity
|
up to 2 years
|
immunophenotyping or characterization of the immune cell subsets in the periphery
Time Frame: In biological samples collected at screening, visit 5/6, end-of-treatment, safety visit and first follow-up visit.
|
Investigate immunological responses.
|
In biological samples collected at screening, visit 5/6, end-of-treatment, safety visit and first follow-up visit.
|
To investigate the role of PET/CT in early response evaluation
Time Frame: up to 2 years
|
PET-CT will be taken at predefined time-points for a subset of patients
|
up to 2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Odd Terje Brustugun, MD, PhD, Vestre Viken Health Trust
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LUNGVAC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oncology
-
State University of New York at BuffaloRecruitingMedical Oncology | Integrative Oncology | Medical Nutrition TherapyUnited States
-
State University of New York at BuffaloRecruitingMedical Oncology | Integrative Oncology | Medical Nutrition TherapyUnited States
-
MaineHealthTufts Medical CenterRecruitingOncology | Prehabilitation | Surgical OncologyUnited States
-
AmgenCompletedCancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology PatientsUnited States
-
AmMax Bio, Inc.CompletedCancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology PatientsUnited States
-
AmgenCompletedCancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology PatientsUnited States
-
Royal Marsden NHS Foundation TrustRecruiting
-
GuerbetRecruitingOncologyAustria, France, Switzerland
-
Centre Hospitalier Regional de HuyCompleted
Clinical Trials on UV1
-
Ultimovacs ASAActive, not recruitingMalignant MelanomaUnited States
-
Ultimovacs ASAOslo University HospitalActive, not recruiting
-
Ultimovacs ASAActive, not recruitingProstate CancerNorway
-
Ultimovacs ASAOslo University HospitalActive, not recruitingA Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer. (UV1-hTERT2012L)Non-small Cell Lung CancerNorway
-
Martin-Luther-Universität Halle-WittenbergUltimovacs ASA; Apotheke der Universitätsmedizin der Johannes Gutenberg-Universität... and other collaboratorsRecruitingHead and Neck Squamous Cell CarcinomaGermany
-
Åslaug HellandBristol-Myers Squibb; Oslo University Hospital; Ultimovacs ASAActive, not recruitingCancer | Mesothelioma | Mesotheliomas Pleural | Cancer of Lung | Cancer, Lung | Mesothelioma; Pleura | Mesothelioma; LungNorway, Denmark, Sweden, Spain, Australia
-
Ultimovacs ASACompletedMalignant MelanomaUnited States, Belgium, United Kingdom, Norway
-
Nordic Society of Gynaecological Oncology - Clinical...Hellenic Cooperative Oncology Group; European Network of Gynaecological Oncological... and other collaboratorsRecruiting